A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma[Formula presented]

Irbaz Bin Riaz, Huan He, Alexander J. Ryu, Rabbia Siddiqi, Syed Arsalan Ahmed Naqvi, Yuan Yao, Muhammad Husnain, Deepa Maheswari Narasimhulu, Jessey Mathew, Qurat Ul Ain Riaz Sipra, Per Olav Vandvik, Richard W. Joseph, Hongfang Liu, Zhen Wang, Vitaly Herasevich, Parminder Singh, Syed A. Hussain, Thai H. Ho, Alan H. Bryce, Lance C. PagliaroMohammad H. Murad, Brian A. Costello

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Context: Identifying the most effective first-line treatment for metastatic renal cell carcinoma (mRCC) is challenging as rapidly evolving data quickly outdate the existing body of evidence, and current approaches to presenting the evidence in user-friendly formats are fraught with limitations. Objective: To maintain living evidence for contemporary first-line treatment for previously untreated mRCC. Evidence acquisition: We have created a living, interactive systematic review (LISR) and network meta-analysis for first-line treatment of mRCC using data from randomized controlled trials comparing contemporary treatment options with single-agent tyrosine kinase inhibitors. We applied an advanced programming and artificial intelligence–assisted framework for evidence synthesis to create a living search strategy, facilitate screening and data extraction using a graphical user interface, automate the frequentist network meta-analysis, and display results in an interactive manner. Evidence synthesis: As of October 22, 2020, the LISR includes data from 14 clinical trials. Baseline characteristics are summarized in an interactive table. The cabozantinib + nivolumab combination (CaboNivo) is ranked the highest for the overall response rate, progression-free survival, and overall survival, whereas ipilimumab + nivolumab (NivoIpi) is ranked the highest for achieving a complete response (CR). NivoIpi, and atezolizumab + bevacizumab (AteBev) were ranked highest (lowest toxicity) and CaboNivo ranked lowest for treatment-related adverse events (AEs). Network meta-analysis results are summarized as interactive tables and plots, GRADE summary-of-findings tables, and evidence maps. Conclusions: This innovative living and interactive review provides the best current evidence on the comparative effectiveness of multiple treatment options for patients with untreated mRCC. Trial-level comparisons suggest that CaboNivo is likely to cause more AEs but is ranked best for all efficacy outcomes, except NivoIpi offers the best chance of CR. Pembrolizumab + axitinib and NivoIpi are acceptable alternatives, except NivoIpi may not be preferred for patients with favorable risk. Although network meta-analysis provides rankings with statistical adjustments, there are inherent biases in cross-trial comparisons with sparse direct evidence that does not replace randomized comparisons. Patient summary: It is challenging to decide the best option among the several treatment combinations of immunotherapy and targeted treatments for newly diagnosed metastatic kidney cancer. We have created interactive evidence summaries of multiple treatment options that present the benefits and harms and evidence certainty for patient-important outcomes. This evidence is updated as soon as new studies are published.

Original languageEnglish (US)
Pages (from-to)712-723
Number of pages12
JournalEuropean Urology
Issue number6
StatePublished - Dec 2021


  • Kidney cancer
  • Living evidence
  • Living systematic reviews
  • Metastatic renal cell carcinoma

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma[Formula presented]'. Together they form a unique fingerprint.

Cite this